- Circassia Pharmaceuticals has announced the initiation of the registration field study for its novel grass allergy immunotherapy.

The study, which will be conducted in over 100 centres in the US, Canada and Europe, will enrol approximately 1,500 subjects.

In previous clinical trials the grass allergy product candidate has achieved encouraging results, with the optimal regimen demonstrating efficacy in subjects who were followed over three grass pollen seasons after completing the short-course treatment before the start of the first season.

At 9:18am: [LON:CIR] Circassia Pharmaceuticals Plc Ord 0.08p share price was +0.95p at 263.85p

Story provided by